Unlocking P(V): Reagents for chiral phosphorothioate synthesis
Knouse KW, deGruyter JN, Schmidt MA, Zheng B, Vantourout JC, Kingston C, Mercer SE, Mcdonald IM, Olson RE, Zhu Y, Hang C, Zhu J, Yuan C, Wang Q, Park P, Eastgate MD, Baran PS. Science. 2018 Aug 2. PubMed
Structural basis for the synergy of 4′- and 2′-modifications on siRNA nuclease resistance, thermal stability and RNAi activity
Harp JM, Guenther DC, Bisbe A, Perkins L, Matsuda S, Bommineni GR, Zlatev I, Foster DJ, Taneja N, Charisse K, Maier MA, Rajeev KG, Manoharan M, Egli M. Nucleic Acids Res. 2018 Aug 11. PubMed
Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier
Godinho BMDC, Henninger N, Bouley J, Alterman JF, Haraszti RA, Gilbert JW, Sapp E, Coles AH, Biscans A, Nikan M, Echeverria D, DiFiglia M, Aronin N, Khvorova A. Mol Ther. 2018 Aug 8. pii: S1525-0016(18)30376-9. PubMed
Titanium implant functionalized with antimiR-138 delivered cell sheet for enhanced peri-implant bone formation and vascularization
Yan J, Chang B, Hu X, Cao C, Zhao L, Zhang Y. Mater Sci Eng C Mater Biol Appl. 2018 Aug 1;89:52-64. PubMed
Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles
Haraszti RA, Miller R, Didiot MC, Biscans A, Alterman JF, Hassler MR, Roux L, Echeverria D, Sapp E, DiFiglia M, Aronin N, Khvorova A. Mol Ther. 2018 Aug 1;26(8):1973-1982. PubMed
Role of Computationally Evaluated Target Specificity in the Hepatotoxicity of Gapmer Antisense Oligonucleotides
Kasuya T, Kugimiya A. Nucleic Acid Ther. 2018 Aug 10. PubMed
Studies of Impending Oligonucleotide Therapeutics in Simulated Biofluids
Domljanovic I, Hansen AH, Hansen LH, Klitgaard JK, Taskova M, Astakhova K. Nucleic Acid Ther. 2018 Aug 14. PubMed
Characterization of the Activity and Distribution of a 2′-O-Methoxyethyl-modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease
Donner AJ, Bell TA, Greenlee S, Graham MJ, Crooke RM. Nucleic Acid Ther. 2018 Aug 22. PubMed
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
Janas MM, Harbison CE, Perry VK, Carito B, Sutherland JE, Vaishnaw AK, Keirstead ND, Warner G. Toxicol Pathol. 2018 Aug 23:192623318792537. PubMed
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase 1b, Multicenter Study
Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. Cancer Discov. 2018 Aug 28. PubMed